Joseph Feczko, MD

Joseph Feczko was until 2009 the Senior Vice President and Chief Medical Officer  (CMO) of Pfizer Inc. and member of the Executive Leadership Team with global responsibilities for all aspects of the company’s medical, regulatory and safety activities.  He is Board Certified (U.S.) in Internal Medicine and Infectious Diseases.  He is currently a member of the Board of Directors of the Foundation for the National Institutes of Health, and Research!America.  He is a member of the Board of Directors of the Accordia Global Health Foundation and a member of the Technical Expert Committee for Trachoma on the International Trachoma Initiative of the Task Force for Global Health.  He served as a member of the governing board of the Technology Strategy Board of the United Kingdom from 2006-2011.



John Rex, MD

John Rex is a distinguished research scientist and a key opinion leader in the field of antimicrobial agents. He held the position of Senior Vice President and Head of Infection, Global Medicines Development at AstraZeneca until October 2016. A 4-year term as the Industry Representative on the US FDA Anti-Infective Drug Advisory Committee gave John the opportunity to have extensive involvement with development of novel regulatory pathways for antimicrobial agents. Following the 2016 sale of the AstraZeneca development pipeline to Pfizer, John moved full-time to consulting. He is an Expert-in-Residence at the Wellcome Trust, a member of the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, and was Chief Strategy Officer for CARB-X. John has an MD from Baylor College of Medicine and is board-certified in Internal Medicine and Infectious Diseases.



Picture of Peter BensonPeter Benson, MSc

During his 25 years in the Life Science industry, Peter Benson has been a senior corporate executive in Big Pharma, start-up CEO, business angel and board member of more than 20 companies, including 6 public, listed companies. In 2010, Peter was closely involved in the successful IPO of Zealand Pharma. Peter holds a Bachelor’s degree in Business Administration from the University of Lund and a Master’s degree in Economics from the University of California. Peter is one of the three co-founders of Sunstone Capital and is the Managing Partner in its Life Science group.



Andreas Segerros, MSc, MBA

Andreas Segerros, a biochemist by training, majoring in biopolymers, from the Royal Institute of Technology in Stockholm and an MBA from Uppsala University. He started at Pharmacia where he spent most of his career. That included senior marketing and business development positions within the Specialty Pharma divisions at the Corporate Office. He headed up the company’s Ophthalmology franchise in the USA and Japan for many years. The Pharmacia years led to valuable experiences of portfolio management and mergers. He has also experienced the life science upstart environment as CEO for Clinitrac, a provider of enabling technologies for pharmaceutical development. Most recently Andreas was Head of Business Development and Operations Planning at Ferring Pharmaceuticals, headquartered in Switzerland. Today, he is a Partner at Sunstone Capital, and advisor to the Swiss biotech Evolva.



Paul Goldenheim, MD

Paul Goldenheim is the CEO of Adenium Biotech and he joined the Board of Directors in January 2015.